Monthly Archives October 2020

CND Life Sciences Receives NIH SBIR Grant to Advance Diagnostic Technology for Neurodegenerative Diseases

PHOENIX, October 26, 2020 / PRNewswire / – Cutaneous NeuroDiagnostics (d / b / a CND Life Sciences), an innovative medical technology company pioneering the detection, visualization and quantification of protein deposits in skin nerve fibers, received an award $ 2.4 million Small Business Innovation Research (SBIR) Phase II Grant from the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH). Todd Levine, MD, neuromuscular neurologist and co-founder and medical director of CND will serve as principal investigator (PI) on the two-year grant.

“We are honored to receive this prestigious grant from NIH,” said Dr. Levine. “The award will support the largest study of its kind aimed at improving the precision and clinical utility of our Syn-One test, which is adopted by neurologists to improve the diagnosis of neurodegenerative disorders, including Parkinson’s disease. “

The NIH grant enables CND to conduct a multicenter clinical study of 500 patients with leading neurologists and academic centers in the United States. The study aims to further validate the sensitivity and specificity of the Syn-One CND test to distinguish between different types of synucleinopathies. This large-scale scientific evaluation of the diagnostic approach and pathological methods of NDT will provide physicians and patients with even greater evidence to support wide clinical adoption of the Syn-One test.

“CND is committed to improving the way physicians diagnose and treat patients with signs and symptoms of neurodegenerative diseases, particularly early in the disease process,” said Richard Morello, Chairman and CEO, CND Life Sciences. “Advancing a convenient, minimally invasive test that can provide physicians and patients with a greater degree of confidence and accuracy in diagnosing difficult conditions such as Parkinson’s disease and Lewy body dementia will help the field to make a big step forward. “

About the Syn-One test

The Syn-One test draws on a decade of science published by global experts and carefully refined laboratory techniques to identify an abnormal form of a protein known as alpha-synuclein. By obtaining three small skin biopsies taken in the patient’s office by the patient’s clinician, the CND applies specialized methods to detect folded phosphorylated alpha-synuclein in the dermal layers of the skin. This abnormal form is a well-known biomarker for a family of diseases called synucleinopathies, the most important type being Parkinson’s disease. A physician ordering Syn-One receives a detailed report of the pathological results of the test, including visual images of the patient’s skin nerve fibers and a determination for the presence of abnormal synuclein.

About synucleinopathies

In the United States, more than 20 million people suffer from movement disorders, cognitive impairment, autonomic dysfunction, and sleep disturbances. A percentage of these patients have signs and symptoms indicative of synucleinopathy, a group of serious neurodegenerative diseases, including Parkinson’s disease and Lewy body dementia, which universally present with abnormal alpha-synuclein. For some of these patients, the absence of objective pathological evidence makes the doctor’s diagnosis and therapeutic choices difficult to determine with certainty. Published studies suggest that even the most experienced neurologists specializing in movement disorders have difficulty making a positive diagnosis of Parkinson’s disease 30% of the time early in the course of the disease.

About CND Life Sciences
Founded in 2017, CND Life Sciences is dedicated to supporting the care of patients with neurodegenerative diseases and other related conditions. Operation of a CLIA certified laboratory in Phoenix, Arizona, CND launched the Syn-One Test ™, the world’s first commercially available test to detect, visualize and quantify the presence of abnormal phosphorylated alpha-synuclein in skin nerve fibers. The test is intended to serve as an objective and evidence-based diagnostic tool to aid in the confirmation of synucleinopathy in patients suspected of Parkinson’s disease (PD), Lewy body dementia (DLB), atrophy multisystem (MSA), pure autonomic insufficiency (PAF) or behavioral disorder in REM sleep (RBD). Thanks to the exclusive staining and analysis of three (3) small skin biopsies performed and provided by a referring clinician, CND offers a practical, precise and minimally invasive alternative to add clarity and confidence in the diagnosis of diseases. neurodegenerative. The company has research collaborations with several biopharmaceutical companies and is committed to advancing science in the field. For more information visit

Disclosure: The research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health under award number R44NS117214. The content is the sole responsibility of the authors and does not necessarily represent the official opinions of the National Institutes of Health.

SOURCE CND Life Sciences

Related links

Source link

Microfluidics Device Market to Gain Ground Through Advances in Diagnostic Technology by 2024 | Global Industry Analysis by Size, Share, Technology Innovation, Demand, and Business Opportunities

Microfluidics Device Market – Overview

Revolutionary developments in diagnostics, drug development and biological research are likely to promote the global market. Medical Device Reports are written by Market Research Future, which includes market options for expansion. An optimistic CAGR is forecast to increase the global market.

The combination of several tests on a chip is expected to improve the market for microfluidic devices in the imminent period. The need to advance treatment efficiency is expected to create promising opportunities for growth in the microfluidic devices market over the coming period.

Download a free sample report (PDF of 350 pages): to know the impact of COVID-19 on this industry @

(*** FREE MRFR COPY SAMPLE of report gives a brief introduction to the research report, industry overview, size and forecast, drivers, challenges, trends including COVID19 impact analysis, full table of contents (123 pages with 143 data tables and 34 report figures), an analysis of key industry players and including key regions. ***)

Segmental analysis of the microfluidic devices market

The segmental study of the Microfluidic Devices market is done on the basis of application, industry, material, and region. On the basis of material, the microfluidic devices market is segmented into Polymer, Glass and Silicon. Based on regions, the microfluidic devices market is segmented into Asia-Pacific, Middle East, North America, Europe, Africa, and Latin America. On the basis of application, the microfluidic devices market is segmented into drug delivery, point-of-care testing, analytical device, pharmaceutical and life science research, environmental and industrial. On the basis of industry, the microfluidic devices market is segmented into medical devices, pharmaceuticals, and in vitro devices.

Detailed Regional Analysis Of Microfluidics Devices Market

The regional assessment of microfluidic devices market is segmented into Asia-Pacific, Middle East, North America, Europe, Africa and Latin America. The North American region is the primary market for microfluidic devices due to the collective understanding of healthcare, increasing elderly population, intensification of chronic diseases and lifestyle, technological advancements for many domestic uses and the evolution of microfluidic equipment for broader insurance infrastructures. The use of these devices has improved with increasing global healthcare spending, as these devices provide accurate, reliable and rapid results for early detection and deterrence of disease. The use of microfluidic devices is high in the North America region, associated with other geographies due to its initial summary and wider applications in industries. The European regional microfluidic device market is driven by increasing diagnostic requirements, due to an upsurge in lifestyle-associated diseases and a growing geriatric population. The global increase in clinical consequences and prerequisites for patients, due to the accessibility to accurate and sensitive diagnostic tests, as well as to state-of-the-art medical equipment and devices.

Competitive analysis of the microfluidic devices market

Advances generated in the market may encapsulate a large part of the market during the forecast period. The improved delivery channels are expected to generate a new level in the market by shortening the lead times. This is likely to impact the long term progress of the global market in the future. The technological evolution of the market is expected to further promote the evolution options during the forecast period. The emergence of significant trends during this period is likely to define the increase in the global market in the coming period. The policies put in place in the various regional markets are expected to stimulate the market in the coming period. The market should realistically return to normal in the coming months, with market leaders controlling the costs of processing. Market conditions are considered austere at first, but are expected to improve in the years to come.

Prolific competitors in the microfluidic device market are Fluidigm Corporation, Bio-Rad Laboratories, Ink, Cepheid, Raindance Technologies, Inc., Johnson & Johnson, Abbott Laboratories, Siemens Healthcare GMBH, Agilent Technologies, Inc., Hoffmann-La Roche AG , Dolomite Center, Micronit Microfluidics, Becton, Dickinson, And Company.

Get the details of the Premium research report, given the impact of COVID-19 @

About Market Research Future:

At Market Research Future (MRFR), we enable our clients to disentangle the complexity of various industries through our Cooked Research Reports (CRR), Semi-Cooked Research Reports (HCRR), Raw Research Reports (3R), Research continuous (CFR)), and market research and consulting services.

The ultimate goal of the MRFR team is to provide top quality market research and intelligence services to our clients. Our market research by components, applications, logistics and market players for global, regional and national market segments, enables our customers to see more, learn more and do more, which helps to answer all of their most important questions.

In order to stay up to date with technology and industry work processes, MRFR often schedules and arranges meetings with industry experts and industry visits for its research analyst members.

Future market research
Office n ° 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: [email protected]

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and, where applicable, we will be looking at covid19 footprints for better analysis of markets and industries. Contact us cordially for more details.

Source link